Journal article icon

Journal article

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update

Abstract:
BACKGROUND: Although significant improvement in efficacy measured by a sustained virological response, the high acquisition costs of direct-acting antivirals limit the access for patients and influence the costs of healthcare resource utilisation in hepatitis C. It is important to have the latest estimates of prevalence, especially in high-risk groups, for cost of illness, cost-effectiveness and budget impact studies. METHODS: Original studies on the estimates of the prevalence among general and high-risk groups in the European Union/European Economic Area (EU/EEA) were retrieved from Medline and Embase for the period from 2015 to 2018. All included studies were evaluated for risk of selection bias and summarised together in a narrative form. Results from previous reviews and updated searches were compared per country among different populations, respectively. RESULTS: Among the 3871 studies identified, 46 studies were included: 20 studies were used for the estimate of the general population; 3 for men who have sex with men (MSM); 6 for prisoners; and 17 for people who inject drugs (PWID). Compared with the results reported in previous systematic reviews, the updated estimates were lower than previously in most available countries. Anti-HCV general population prevalence estimates ranged from 0.54 to 1.50% by country. The highest prevalence of anti-HCV was found among PWID (range of 7.90-82.00%), followed by prisoners (7.00-41.00%), HIV-positive MSM (1.80-7.10%), HIV-negative MSM (0.20-1.80%), pregnant women (0.10-1.32%) and first-time blood donors (0.03-0.09%). CONCLUSIONS: Our study highlights the heterogeneity in anti-HCV prevalence across different population groups in EU/EEA. The prevalence also varies widely between European countries. There are many countries that are not represented in our results, highlighting the need for the development of robust epidemiological studies.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1186/s12879-019-4284-9
Publication website:
https://flore.unifi.it/bitstream/2158/1357458/2/s12879-024-09241-z.pdf

Authors

More by this author
Role:
Author
ORCID:
0000-0002-4851-1462
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-0938-0826
More by this author
Role:
Author
ORCID:
0000-0003-2278-3352
More by this author
Role:
Author
ORCID:
0000-0001-7939-7204


Publisher:
BioMed Central
Journal:
BMC Infectious Diseases More from this journal
Volume:
19
Issue:
1
Pages:
655-655
Publication date:
2019-07-23
Acceptance date:
2019-07-12
DOI:
EISSN:
1471-2334
ISSN:
1471-2334


Language:
English
Keywords:
Pubs id:
2392429
Local pid:
pubs:2392429
Source identifiers:
W2963850354
Deposit date:
2026-03-21
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP